The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Motormouth it was 10 k investment as I thought it would not just be delisted,an I said this ,if you care to read just prior to the 250% rise. 25/26 /27th
There was nothing more to say.
Now I believe it will be delisted but not at the price I paid.
0.80 I paid . 3p is the offer.
Donk.
Who remembers the XTR Sorter needs to be upgraded to deal with the larger ore at RHA .
Big carrot 2 years ago. 5 billion shares back then up from 1 billion.
Geez man when will you stop pumping the balderdash.
600k in salaries just for GR since then,now your wetting your selves for the lights to be turned on .
Mental.
Which Horse is that CF3.
The one that said RHA is on track to 1st production. 3 years ago.
Or the one that has lent the company money to pay his own salary because he could not Dillute no more.
Or the one that keeps buying new Acquisitions With Shareholders because he knows the others are not viable .
Or the one that always seems to promise jam tomorrow.
Mcpoo mcpoo please calm down, as I’ve said I sold out from this Ponzie at 0.32 that’s double today Sp
That said share some complacency for holders who’ve been stuck in this disastrous run company, they have supported this company,an may of averaged down from a penny but yet still Severely underwater the water.
They I’m sure don’t want muppets like your self giving false hope only for the price to spike letting the normal pump crew run of with there 10 or so %
This will be Red tomorrow you can bet your bottom dollar.
Also DFX made a 250% rise yesterday with out any pump on my part .
You’d probably **** your self .
Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.
What I like about PYC they don’t put out willy Nilly RNS about there Steps an there Fight an Technology to enhance the benefits of Cancer Suffering .
Looking Forward to the Next contract.